Dabixta 75
Form: Capsule
Strength: 75mg
Generic Name: Dabigatran
Company: Unimed Unihealth Pharmaceuticals Ltd.
MRP:৳ 75.0 (Capsule)
Is Antibiotic: No
Indications
Dabixta 75 is used to reduce the risk of stroke and blood clots in patients with non-valvular atrial fibrillation. Dabixta 75 is also used to treat deep vein thrombosis (DVT) and pulmonary embolism (PE) in patients who have already been treated with a blood thinner for 5-10 days. Dabixta 75 helps prevent the recurrence of DVT and PE in patients who have been previously treated. Additionally, Dabixta 75 is used to prevent DVT and PE in patients who have had hip replacement surgery.
Pharmacology
Dabixta 75 works by blocking thrombin, an enzyme that helps blood clot. By preventing thrombin from working, Dabixta 75 stops the formation of blood clots. This helps to reduce the risk of stroke and embolism. The active parts of the medication can stop both free and clot-bound thrombin from causing blood clots and also prevent platelets from clumping together.
Dosage & Administration
For Stroke and Systemic Embolism in Non-valvular Atrial Fibrillation:
– If kidney function is normal (CrCl >30 mL/min): 150 mg twice a day
– If kidney function is reduced (CrCl 15-30 mL/min): 75 mg twice a day
Treatment of DVT and PE:
– If kidney function is normal (CrCl >30 mL/min): 150 mg twice a day after 5-10 days of injectable blood thinners.
Prevention of DVT and PE Recurrence: 150 mg twice a day after previous treatment if kidney function is normal.
Prevention of DVT and PE After Hip Replacement:
– If kidney function is normal (CrCl >30 mL/min): 110 mg on the first day, then 220 mg once a day.
– Temporarily stop the medication before surgery, then start Dabixta 75 again after the procedure.
Pediatric Use: The safety and effectiveness in children have not been established.
Elderly Use: This medicine is safe for older adults, but they may be at a higher risk for stroke and bleeding.
Interaction
For Stroke and Embolism Risk: Taking this medicine with P-gp inducers (like rifampin) reduces its effect and should be avoided.
For DVT and PE Treatment: Avoid using this medicine with P-gp inhibitors if kidney function is poor (CrCl <50 mL/min).
For DVT and PE Prevention After Hip Surgery: In patients with normal kidney function (CrCl ≥50 mL/min), taking this medicine with P-gp inhibitors (such as dronedarone or ketoconazole) may need special timing to separate doses.
Contraindications
Dabixta 75 should not be used by patients with active bleeding, those who have had serious allergic reactions to Dabixta 75, or those with mechanical heart valves.
Side Effects
Stopping this medication too soon can increase the risk of blood clots. Dabixta 75 also increases the risk of bleeding, which can be severe or even fatal. Common side effects include stomach upset, indigestion, and a burning sensation in the stomach. Some people may have an allergic reaction.
Pregnancy & Lactation
The safety of this medication during pregnancy has not been proven. Dabixta 75 is not recommended while breastfeeding.
Precautions & Warnings
Stopping the medication too soon can lead to blood clots. There is also a risk of serious bleeding. Spinal or epidural hematomas may occur in patients who are undergoing spinal procedures while on this medicine. This medication is not safe for patients with mechanical heart valves. Dabixta 75 should not be taken with certain drugs that reduce its effectiveness.
Overdose Effects
An overdose can cause serious bleeding. If this happens, the medicine should be stopped, and the bleeding source should be found. A reversal agent (idarucizumab) is available for this situation.
Therapeutic Class
Dabixta 75 belongs to the class of anticoagulants, anti-platelet drugs, and fibrinolytics (thrombolytics).
Storage Conditions
Store at a temperature not exceeding 30°C in a dry place. Keep away from light and moisture.
Similar Brands of Dabigatran (Capsule – 75mg)
| Brand Name | Form | Strength | Company | MRP (৳) |
|---|---|---|---|---|
| Dabiren 75 | Capsule | 75mg | Renata Limited | 75.0 |